What happens to body chemicals when people with alcohol problems take a diabetes-like medicine?

Original Title

Effect of the GLP‐1 receptor agonist exenatide on pro‐inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double‐blinded, placebo‐controlled clinical trial

Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms

Summary

People with alcohol use disorder have more inflammation and different hormone levels than others. Scientists gave them a drug called exenatide, which helps with diabetes and reduces inflammation in other diseases, to see if it helps fix these body chemicals.

Sign up to see full results

Get access to research results, context, and detailed analysis.

Surprising Findings

Exenatide, a GLP-1 drug that reduces inflammation in diabetes and obesity, had no effect on any of the 25 biomarkers in people with AUD after 26 weeks.

GLP-1 drugs are known to reduce inflammation and improve heart health in other conditions, so scientists expected at least some benefit in AUD, especially given animal studies showing reduced alcohol use.

Practical Takeaways

If you or someone you know struggles with alcohol, getting blood work done (like hsCRP or liver panels) might reveal hidden health risks even without obvious symptoms.

medium confidence

Unlock Full Study Analysis

Sign up free to access quality scores, evidence strength analysis, and detailed methodology breakdowns.